Creative Touch Permanent Makeup and Aesthetics

Cold atmospheric plasma is a partially ionised gas generated at or near room temperature that delivers a controlled stream of reactive oxygen and nitrogen species (RONS) to tissue surfaces. Its primary mechanism is dose-dependent modulation of cellular signalling: at therapeutic doses it suppresses the inflammatory cytokines that actively impair barrier function, stimulates fibroblast proliferation through TGF-β pathways, and disrupts microbial membrane integrity without antibiotic resistance risk. The strongest clinical evidence supports its use in inflammatory skin conditions – particularly atopic dermatitis – where it reduces IL-4 and IL-13 activity, lifting the cytokine suppression of filaggrin and ceramide synthesis. Its role in aesthetic rejuvenation is mechanistically well-supported but awaits larger controlled trials. At Creative Touch, CAP functions primarily as an environment-restoring treatment – resolving the inflammatory conditions that impair the tissue’s response to regenerative interventions.

Cold atmospheric plasma (CAP) is a partially ionised gas produced at atmospheric pressure and temperatures low enough for direct tissue contact – typically operating below 40°C at the point of application. It belongs to the same physical category as plasma in the conventional sense – the fourth state of matter, in which sufficient energy is applied to a gas to ionise a fraction of its molecules – but unlike thermal plasma (used in arc welding or plasma cutting), the energy input is controlled to ionise only a small proportion of the carrier gas whilst keeping the bulk temperature close to ambient. The result is a reactive, electrically active gas stream that can be applied to living tissue without thermal injury. ^[10]

What Cold Atmospheric Plasma Is

The “plasma” in CAP is not a drug, a serum, or a platelet preparation – it is a physical state of matter. A carrier gas (typically helium, argon, or air) is passed through an electrical field that ionises a fraction of its molecules, generating a mixture of ions, free electrons, UV photons, and – critically – reactive oxygen and nitrogen species (RONS). It is the RONS fraction that is biologically active at the tissue level. ^[10]

The choice of carrier gas is not cosmetically neutral. Helium and argon plasmas operate at lower gas temperatures than air plasma, producing a cooler, more controllable output that makes them better suited to superficial tissue applications. Research comparing gas types in cytokine reduction models found that helium and argon plasma were more effective than air plasma at reducing IL-13, IL-31, and IL-12 in atopic skin models – a difference attributed to the distinct RONS profiles each carrier produces and the thermal stress that air plasma imposes on already-compromised tissue. ^[12] Device formats vary: plasma jet systems deliver a focused stream of ionised gas directly to a localised area, whilst dielectric barrier discharge (DBD) devices generate plasma across a broader surface contact area. Both deliver therapeutic RONS, but differ in penetration depth, treatment area per pass, and the balance of reactive species produced.

How It Works: The RONS Mechanism

The biological effects of CAP are mediated by the reactive oxygen and nitrogen species it deposits at the tissue surface – molecules including superoxide, hydrogen peroxide, hydroxyl radicals, nitric oxide, and peroxynitrite. These are the same reactive species that human immune cells produce during normal antimicrobial and wound-healing responses; CAP delivers them exogenously, at a controlled dose, without requiring the biological cascade that normally generates them. ^[1]

The dose-dependence of this mechanism is important to understand. RONS are not inherently beneficial or harmful – their effect depends entirely on concentration and cellular context. At low therapeutic doses, RONS activate NF-κB signalling in quiescent fibroblasts, promoting proliferation and upregulating procollagen synthesis; a 2017 Nature Scientific Reports study confirmed that low-temperature plasma promoted fibroblast proliferation and migration through this pathway. ^[5] At higher doses – or in already-inflamed tissue where oxidative stress is elevated – the same NF-κB pathway becomes pro-inflammatory and cytotoxic. This is why device calibration, treatment duration, and the inflammatory state of the target tissue all materially affect outcomes.

Suppressing the Inflammatory Environment

In tissue where inflammation is actively suppressing normal cellular function – the situation in atopic dermatitis, reactive barrier disruption, and certain post-procedure states – CAP’s most clinically significant action is not stimulation but resolution. The RONS generated at therapeutic doses modulate NF-κB in a net anti-inflammatory direction in already-activated immune cells, reducing production of IL-4, IL-13, and IL-31 – the type 2 cytokines responsible for the filaggrin suppression and ceramide synthesis inhibition described in the Filaggrin and Ceramides entities. ^[12] A 2021 prospective comparative clinical pilot study published in Nature Scientific Reports found significant reductions in SCORAD and EASI scores (validated atopic dermatitis severity measures) following CAP treatment, with improvement in skin barrier function measured by TEWL. ^[4]

This anti-inflammatory action has a downstream consequence that matters for treatment planning: by reducing IL-4 and IL-13, CAP lifts the cytokine-mediated suppression of ELOVL4 (the elongase responsible for very-long-chain fatty acid synthesis) and SPT ( serine palmitoyltransferase, the rate-limiting enzyme initiating ceramide synthesis). In practice, this means the skin’s own ceramide and barrier lipid production capacity can recover – provided the inflammatory environment is resolved and the suppression is lifted. CAP does not directly deliver ceramides or stimulate their synthesis in the way that niacinamide does; it removes the signal that was blocking synthesis.

Antimicrobial Action

RONS generated by CAP disrupt bacterial, fungal, and viral lipid membranes through oxidative attack – a mechanism that does not induce the adaptive resistance that conventional antimicrobials do, since RONS target multiple membrane components simultaneously rather than a single molecular target. ^[10] This is clinically relevant for barrier-disrupted skin where microbiome dysbiosis – particularly Staphylococcus aureus overgrowth – perpetuates the inflammatory cycle. A 2025 helium/argon device safety assessment using a pig model confirmed tissue safety at therapeutic doses whilst demonstrating effective antimicrobial activity at the tissue surface. ^[13]

Microbiome Rebalancing: The Three-Channel Approach

CAP’s antimicrobial action in dysbiotic skin is more nuanced than membrane disruption of individual organisms. Its effect on the skin microbiome operates through three independent channels simultaneously – which together distinguish it from antibiotics, which reduce bacterial populations broadly without community rebalancing.

Channel one – selective S. aureus reduction. RONS generated by CAP are particularly effective against S. aureus biofilm, achieving multi-log reductions in viable biofilm cells in laboratory conditions. ^[6] Biofilm architecture is precisely what protects S. aureus from both host immune clearance and topical antibiotic penetration; its disruption removes the physical defence that enables chronic S. aureus persistence in dysbiotic skin. Critically, repeated CAP application does not select for S. aureus resistance – the RONS mechanism targets multiple membrane components simultaneously rather than a single molecular target, removing the selection pressure that drives resistance accumulation with conventional antimicrobials. ^[7]

Channel two – macrophage-enhanced pathogen clearance. CAP additionally enhances macrophage killing activity against S. aureus, including antibiotic-resistant MRSA strains, through oxidative mechanisms. ^[2] This matters because biofilm-forming S. aureus is specifically adapted to evade macrophage phagocytosis; CAP addresses the immune evasion mechanism directly, restoring host clearance capacity alongside its direct antimicrobial effect.

Channel three – tight junction restoration. CAP treatment has been shown to restore tight junction integrity in keratinocytes, demonstrated in a 2022 study of psoriatic skin. ^[3] This is mechanistically significant beyond the antimicrobial effect: tight junction disruption independently collapses the lower stratum corneum pH zone, contributing to the acid mantle alkaline shift that sustains dysbiosis. Restoring tight junction integrity supports pH normalisation from below – complementing surface-level acid mantle support and creating conditions in which commensal organisms can re-establish.

The net clinical evidence for this three-channel model is a 2025 sequenced clinical study (Watanabe, n=10, pilot) in acne and atopic dermatitis patients demonstrating S. aureus proportion reduced from 4.2% to 2.1% in AD patients, S. epidermidis relative abundance increased, and Simpson’s Diversity Index significantly improved (p=0.045) – confirming that the community became more balanced rather than simply smaller. ^[11] The distinction from antibiotics is the key clinical point: CAP reduces the pathogen whilst enabling commensal recovery, rather than depleting the entire microbial community.

Note on sequencing CAP reduces S. aureus biofilm load and restores tight junction infrastructure – it does not reconstitute the commensal community. The habitat must be actively supported after treatment: pH-appropriate cleanser, multi-lipid barrier product, and microbiome-supportive ingredients. CAP creates the ecological opportunity for commensal recovery; the homecare protocol provides the environment in which that recovery can consolidate.

Fibroblast Activation and Collagen Signalling

In non-inflamed or post-inflammatory tissue, where the primary deficit is reduced synthesis capacity rather than active suppression, CAP’s RONS activate TGF-β signalling in fibroblasts – stimulating procollagen production and supporting extracellular matrix remodelling. This positions CAP as a genuine, if modest, collagen-stimulating agent in the appropriate tissue context. The evidence base for this application is mechanistically well-established but currently supported by in vitro and early clinical data rather than large controlled trials in aesthetic rejuvenation populations. ^[5]

Evidence Base

An honest assessment of the current evidence is warranted. CAP’s clinical evidence varies considerably across its applications, and the distinction matters for realistic treatment planning.

The strongest evidence base is in inflammatory and infectious skin conditions. Multiple study designs across wound healing and antimicrobial applications have demonstrated consistent positive signals, with a 2025 Frontiers in Medicine review summarising the cellular and clinical mechanisms underpinning CAP’s efficacy across chronic and acute wounds. ^[8] A 2025 randomised single-blind trial in chronic wound management confirmed statistically significant improvements in wound closure rates compared to standard care. ^[9] For atopic dermatitis specifically, both objective measures ( TEWL, SCORAD) and quality of life measures showed improvement in controlled studies. ^[4] This is Tier 1–2 evidence: replicated, human clinical data with validated outcome measures.

For aesthetic rejuvenation – skin texture, tone, collagen density – the evidence is at an earlier stage. Mechanistic pathways are established, and early clinical observations are positive, but large, well-controlled trials with standardised outcome measures comparable to the atopic dermatitis literature are not yet available. This is honest Tier 2–3 territory: mechanistically plausible, supported by in vitro and pilot data, with clinical consensus building but not yet consolidated. ^[1]

Clinical Pearl The distinction matters practically: CAP is a well-evidenced intervention for inflammatory barrier conditions and a promising but still-emerging one for structural skin rejuvenation. Conflating the two in client communications overstates the evidence for one and undersells the genuine strength of the other.